European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading

MT Newswires Live
02-14

European equities traded in the US as American depositary receipts were tracking slightly lower late Thursday morning, declining 0.04% to 1,402.70 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and biotech company BioNTech (BNTX), which climbed 14.9% and 6.3% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech company and Evaxion Biotech (EVAX), which rose 5.6% and 1.5% respectively.

The decliners from continental Europe were led by consumer goods company Unilever (UL) and pharmaceutical company Novo Nordisk (NVO), which fell 5% and 3% respectively. They were followed by telecommunications company Nokia (NOK) and financial services company Banco Santander (SAN), which were off 0.5% each.

From the UK and Ireland, the gainers were led by biopharmaceutical company Amarin (AMRN) and pharmaceutical company Silence Therapeutics (SLN), which increased 6.7% and 3.3% respectively. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company NuCana (NCNA), which were up 2.6% and 2.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company TC Biopharm (TCBP) and tobacco company British American Tobacco (BTI), which shed 16.3% and 9.1% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and financial services company Barclays (BCS), which were down 6.7% and 4.8% respectively.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10